• Why Are We Focused on Simulation-based Methods for Predicting Binding Affinity?

    Nov 14 | Bio-IT World | Early computational drug discovery relies on accurate predictions of binding affinity. If we can accurately predict the affinity of molecule designs, we can dramatically reduce the number of compounds that we need to synthesize and test when optimizing new drug candidates. More

  • Why Overlooking Female Biology Still Impairs Drug Development

    Nov 12 | Bio-IT World | Though gender equity efforts in research have made strides, progress has plateaued. Roughly two-thirds of pivotal clinical trials leading to the U.S. Food and Drug Administration (FDA) drug approvals now include women at rates proportional to their disease burden, but the problem is fundamental issues in not considering female biology. More

  • United Genetic, Epigenetic Readouts From The Same DNA Molecule

    Nov 11 | Bio-IT World | Watchmaker Genomics has launched TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology. More

  • Revolutionizing ADC Manufacturing: How Single-Use Technologies Are Reshaping Biopharma Efficiency and Safety

    Nov 06 | Bio-IT World | Antibody-drug conjugates (ADCs) are among the most promising and complex therapeutics in modern oncology. The global ADC market is growing at an extraordinary pace. Yet, this promise comes with complexity. Multi-step conjugations, long processing times, highly potent raw materials, and stringent quality requirements pose significant manufacturing challenges. More

  • DNA Nanotech Brings Precision Drug Monitoring to At-Home Use

    Nov 05 | Bio-IT World | For millions of patients prescribed drugs with a narrow therapeutic window, safe dosing depends on therapeutic drug monitoring. But outside of hospital labs equipped with specialized machines and trained staff, monitoring drug concentrations in real time has been largely out of reach. DNA nanotechnology may hold the key to bringing this critical capability to the point of care—and even into patients’ homes. More

  • PacBio Aims for Sub-$300 Genomes with Reusable SMRT Cells

    Nov 04 | Bio-IT World | Pacific Biosciences announced a chemistry upgrade and SMRT cell reuse capability last month at the American Society of Human Genetics (ASHG) meeting. CEO Christian Henry said the moves targeted dramatic price reductions for customers and to compete with short-read sequencing. More

  • NVIDIA Unveils Quantum-AI Integration and Record-Breaking Blackwell Architecture at GTC 2025

    Oct 30 | Bio-IT World | NVIDIA CEO Jensen Huang used NVIDIA’s GTC 2025 keynote to share his vision for the convergence of quantum computing and artificial intelligence, while revealing staggering demand for the company’s next-generation Grace Blackwell architecture that signals a fundamental shift in how the world computes. More

  • SandboxAQ Releases New AI Model, Illumina Launches New Business, Thermo Fisher’s New Analyzer

    Oct 29 | Bio-IT World | SandboxAQ releases AQCat25-EV2, a new quantitative AI model trained on the AQCat25 dataset; Illumina launches BioInsight, a new business within Illumina developed to meet industry demand for deeper biologic insights; Thermo Fisher Scientific introduces the Applied Biosystems SwiftArrayStudio Microarray Analyzer; and more. More

  • Follow the Money: Potential Best-in-Category Weight Loss Drug, Tubulis’ ADC Advancement, Trojan Horse Treatment for Cancer

    Oct 28 | Bio-IT World | Kailera Therapeutics advances injectable dual GLP-1/GIP receptor agonist; Tubulis develops antibody-drug conjugate for ovarian cancer and lung adenocarcinomas; Trogenix advances their pipeline of potentially curative cancer therapies across multiple aggressive solid tumors into the clinic; and more. More

  • AI Model Turns Health Data Into Disease Forecasts

    Oct 23 | Bio-IT World | Researchers have developed a generative transformer model capable of forecasting an individual’s risk of developing over 1,200 diseases a decade in advance. The model, called Delphi-2M, was validated using data on about 2 million individuals from Denmark’s National Patient Registry without retraining. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!